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University, Palo Alto, California, USAIntroduction: Coronary artery calcium (CAC) is highly prevalent and linked with poor outcomes in patients
receiving maintenance hemodialysis, and its reduction may improve patient prognosis. SNF472, a se-
lective inhibitor of hydroxyapatite crystallization, slows CAC progression in patients receiving mainte-
nance hemodialysis. In this analysis, we assessed the efficacy of SNF472 in prespecified patient
subgroups.
Methods: In a randomized clinical trial SNF472 300 mg, SNF472 600 mg, or placebo were infused thrice
weekly in 91, 92, and 91 patients receiving maintenance hemodialysis and with CAC at baseline, respec-
tively. In prespecified subanalyses, the percent change in CAC volume score (CACvs) from baseline to
week 52 in modified intention-to-treat (mITT) and per-protocol (PP) populations was calculated in the
following subgroups: age, sex, diabetes mellitus, dialysis vintage, prior atherosclerotic cardiovascular
disease, baseline use of non-calcium and calcium-based phosphate binders, calcimimetics, activated
vitamin D, warfarin, and statins.
Results: In the main trial, SNF472 significantly reduced CACvs progression compared with placebo (11%
versus 20%mITT analyses; P ¼ 0.016; 8% vs. 24% PP analyses; P < 0.001). Treatment differences for CACvs
progression were similar across all subgroups, and all interaction P values were non-significant in mITT
and PP analyses.
Conclusions: SNF472 treatment for 52 weeks reduced CACvs progression compared with placebo in a
broad range of patients receiving maintenance hemodialysis. Future studies will determine the impact of
SNF472 on cardiovascular events in this population.
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AC is highly prevalent and linked with an
increased risk of morbidity and mortality in pa-
tients with end-stage kidney disease (ESKD).1 In these
patients, CAC accumulates in the arterial intimaspondence: Paolo Raggi, Division of Cardiology, University
erta, 5A9-014, 11220 83rd Avenue NW, Edmonton, Alberta
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mber 2020; published online 4 November 2020within atherosclerotic plaques and in the media layer
due to dysregulation of mineral metabolism.2 CAC is
associated with a variety of cardiovascular events
such as acute and chronic coronary artery syndromes,
heart failure with preserved and reduced ejection frac-
tion, cardiac arrhythmias, and sudden death.1
Although the initiating stimulus may be different,
all calcification processes ultimately depend on the
formation of calcium phosphate crystals and, in most
cases, they result in the deposition of aKidney International Reports (2020) 5, 2178–2182










Age, yr, mean  SD 64.1  8.2 63.3  9.0 63.5  8.9
Female 33 (36.2) 74 (40.4) 107 (39.0)
Dialysis vintage, mo, median
(range)
34.5 (6–263) 44.3 (7–521) 41 (6–521)
Diabetes mellitus 60 (65.9) 114 (62.2) 174 (63.5)
Atherosclerotic cardiovascular
disease
45 (49.5) 70 (38.3) 11 (40.1)
Non-calcium-based phosphate
binders
55 (60.4) 119 (65.0) 174 (63.5)
Calcium-based phosphate binders 26 (28.6) 55 (30.0) 81 (29.5)
Calcimimetics 26 (28.6) 60 (32.7) 86 (31.3)
Activated vitamin D 47 (51.6) 97 (53.0) 144 (52.5)
Warfarin 5 (5.5) 13 (7.1) 18 (6.5)
Statins 53 (58.2) 115 (62.8) 168 (61.3)
aValues shown are n (%) unless otherwise stated.
bPatients could take both calcium-based and non–calcium-based phosphate binders
simultaneously.
Table 2. Serum calcium, phosphorus, and intact parathyroid
hormone at baseline and week 52
Analyte
Mean ± SD, (N)
Placebo (N [ 90) Combined Dose (N [ 183)
Calcium, mmol/L
Baseline 2.18  0.17 (84) 2.22  0.19 (164)
Week 52 2.23  0.18 (73) 2.23  0.18 (183)
Phosphorus, mmol/L
Baseline 1.42  0.51 (32) 1.31  0.38 (60)
Week 52 1.49  0.53 (35) 1.39  0.51 (70)
Intact parathyroid hormone,
pmol/L
Baseline 48.3  41.0 (84) 44.6  36.7 (161)
Week 52 46.0  37.9 (71) 39.0  32.5 (149)
P Raggi et al.: Subgroup Analyses of CALIPSO CLINICAL RESEARCHhydroxyapatite solid phase. SNF472 is an intravenous
formulation of the hexasodium salt of myo-inositol
hexaphosphate with highly effective in vitro and
in vivo inhibition of hydroxyapatite nucleation and
crystal formation.3 In the phase 2b Calcifactant for
Acute Lung Injury in Pediatric Stem Cell Transplant
and Oncology Patients (CaLIPSO) trial of patients
receiving maintenance hemodialysis, SNF472 signifi-
cantly reduced the progression of CACvs compared
with placebo in an mITT population, and the effect
was confirmed in a PP population.4 In this report,
we present results of prespecified patient subgroup
analyses.
METHODS
The study design has been published in detail before.5
Briefly, we randomized 274 adult patients (18 to 80
years old) on maintenance hemodialysis for $6
months, with diabetes mellitus if younger than 55
years of age, and baseline CAC Agatston score between
100 and 3500 units on a screening noncontrast multi-
detector computed tomography to placebo, 300 mg, or
600 mg of SNF472 infused thrice weekly during he-
modialysis for 52 weeks. The Agatston CAC score is
commonly used in clinical practice; however, the
CACvs is more reproducible. Therefore, the CACvs was
used to measure CAC change.6 Multidetector computed
tomography imaging was performed at enrollment and
at week 52, or as soon as feasible after voluntary
withdrawal or kidney transplantation. An experienced
radiologist blinded to patient data, including treatment
assignment, reviewed the quality of all scans for
acceptability and measured CACvs. A portion of all
scans (w15%) was reviewed by an expert readerKidney International Reports (2020) 5, 2178–2182blinded to treatment allocation to assess inter-reader
agreement. The study was approved by the research
ethics committee of each participating institution and
the trial was conducted according to the principles of
the Declaration of Helsinki.
The primary efficacy analysis model was an analysis
of covariance with the change in log score (log[week
52] – log[baseline]) as the dependent variable, and a
fixed effect term for randomized treatment group as
well as log(baseline) as covariates; the model was
stratified by baseline Agatston CAC score. The geo-
metric least square means and 95% confidence in-
tervals were estimated and back-transformed to yield
mean percent change from baseline to week 52 for the
primary analysis of the combined SNF472 groups
compared with placebo. The primary analyses were
conducted on an mITT population (patients who
received at least 1 dose of SNF472 or placebo and had
an evaluable multidetector computed tomography at
baseline and 52 weeks, or any time during follow-up if
a patient was discontinued prematurely from the
study). The PP population included those in the mITT
who met all study entry criteria, received at least 80%
of study drug, and had a week-52 visit and multi-
detector computed tomography scan. We report results
in predefined subgroups at baseline: age (<65 or $65
years), sex, diabetes mellitus, dialysis vintage (<2, 2
to <5, $5 years), prior atherosclerotic cardiovascular
disease, non-calcium and calcium-based phosphate
binders, calcimimetics, activated vitamin D, warfarin,
and statins.
RESULTS
Table 1 shows the patient characteristics of the pla-
cebo and pooled SNF472 cohorts. Table 2 shows the
baseline and week-52 serum levels of calcium, phos-
phorus, and intact parathyroid hormone for the placebo
and the combined SNF472 treatment groups. In the
primary analyses, SNF472 significantly reduced
progression of log CACvs compared to placebo2179
Figure 1. Progression of coronary artery calcium volume score in patient subgroups (modified intention-to-treat analyses). CAC, coronary artery
calcium; CI, confidence interval; mITT, modified intention to treat; Pi, phosphate.
CLINICAL RESEARCH P Raggi et al.: Subgroup Analyses of CALIPSO(mITT: 11% vs. 20%, P ¼ 0.016; PP: 8% vs. 24%,
P < 0.001). Figure 1 shows the difference in pro-
gression of CACvs in the prespecified subgroups in
mITT analyses. Figure 2 shows the difference in
progression of CACvs in the prespecified subgroups
in the PP analyses. All interactions were nonsig-
nificant and SNF472 consistently reduced progres-
sion of CACvs in all prespecified subgroups.DISCUSSION
Vascular calcification is a complex phenomenon
involving numerous active and passive mechanisms.
The final step requires nucleation of calcium phosphate
crystals that lead to the formation of a hydroxyapatite2180solid phase. SNF472 is a first-in-class inhibitor of
crystallization of calcium and phosphorus, whose
metabolism is highly dysregulated in ESKD. Several
factors have been associated with CAC progression.
Age is most influential, as atherosclerosis is almost
universal among adult individuals. In the general
population, men show an earlier onset and larger
accumulation of CAC compared to women,7 although
this difference may be attenuated in ESKD. Diabetes
mellitus is a strong predictor of progression of CAC in
the general population and in ESKD where it is often
associated with low turnover bone disease and accel-
erated vascular calcification.8 Prior atherosclerotic
cardiovascular disease is an obvious risk factor for the
progression of CAC, whereas time on dialysisKidney International Reports (2020) 5, 2178–2182
Figure 2. Progression of coronary artery calcium volume score in patient subgroups (per-protocol analyses). CAC, coronary artery calcium; CI,
confidence interval; Pi, phosphate.
P Raggi et al.: Subgroup Analyses of CALIPSO CLINICAL RESEARCHpredisposes to CAC accumulation through continuing
exposure to dysregulated mineral and bone meta-
bolism, as well as chronic inflammation and oxidative
stress.9 Some medical interventions appear to affect
CAC progression. Warfarin and statins, through a
probable interference with natural inhibitors of calci-
fication, have been associated with progression of
CAC.10 Large doses of active vitamin D may accelerate
and calcimimetics may reduce CAC progression.11,12
The non–calcium-based phosphate binders are the
only class of drugs that have been shown in open-
label randomized clinical trials to reduce progression
of CAC when compared to calcium-based binders.13,14
SNF472 demonstrated similar efficacy in all sub-
groups, showing that inhibition of hydroxyapatiteKidney International Reports (2020) 5, 2178–2182crystallization with this agent can reduce progression
of CAC independently of comorbidities or concomitant
treatments.
This study had several limitations: we did not record
or analyze calcium and phosphate balance during or
between dialysis sessions and we did not mandate a
single dialysate calcium concentration in the CALIPSO
study. However, it is unlikely that variability in these
parameters could explain the treatment effect in a ran-
domized double-blind controlled study where patient
cohorts had similar baseline clinical characteristics. We
did not measure serological markers of bone metabolism.
A meta-analysis of several randomized controlled
trials comparing non–calcium-based to calcium-based
phosphate binders suggested that the former reduce2181
CLINICAL RESEARCH P Raggi et al.: Subgroup Analyses of CALIPSOCAC progression and might reduce mortality in
ESKD.15 Larger and longer-term studies of SNF472 will
be required to determine whether SNF472 can reduce
the frequency of heart failure, stroke, sudden cardiac
death, and other complications associated with coro-
nary, cerebrovascular, and peripheral arterial calcifi-
cation in ESKD.DISCLOSURES
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